Subscriber access provided by RYERSON UNIV
Article
Nrf2 Knockdown Disrupts the Protective Effect of Curcumin on Alcohol-Induced Hepatocyte Necroptosis Chunfeng Lu, Wenxuan Xu, Feng Zhang, Jiangjuan Shao, and Shizhong Zheng Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.6b00562 • Publication Date (Web): 20 Oct 2016 Downloaded from http://pubs.acs.org on October 22, 2016
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
Title
2
Nrf2 Knockdown Disrupts the Protective Effect of Curcumin on Alcohol-Induced Hepatocyte
3
Necroptosis
4 5
Running title
6
Curcumin prevents hepatocyte necroptosis
7 8
Authors
9
Chunfeng Lu,a Wenxuan Xu,b Feng Zhang,a,b Jiangjuan Shao,a Shizhong Zheng a,b,*
10 11
Affiliations
12
a
13
Jiangsu, China
14
b
15
University of Chinese Medicine, Nanjing, Jiangsu, China
Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing,
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing
16 17
Correspondence
18
*
19
Chinese Medicine, 138 Xianlin Avenue, Nanjing 210023, Jiangsu, China. Tel.: +86 25 85811246; Fax:
20
+86 25 86798188. E-mail address:
[email protected].
Address correspondence to: Department of Pharmacology, School of Pharmacy, Nanjing University of
21 22
1
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 2 of 34
23
Abbreviations
24
ALD, alcoholic liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
25
DAMPs, damage-associated molecular patterns; DMEM, Dulbecco’s modified eagle medium; DMSO,
26
dimethylsulfoxide; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; GAPDH,
27
glyceraldehyde phosphate dehydrogenase; H&E, Haematoxylin-eosin; HMGB1, high-mobility group
28
box 1; ISH, in situ hybridization; JNK, c-jun N-terminal kinase; MLKL, mixed lineage kinase
29
domain-like; NQO1, NAD(P)H: quinone oxidoreductase 1; Nrf2, nuclear factor (erythroid-derived
30
2)-like 2; NS, normal saline; RIP1, receptor-interacting protein 1; RIP3, receptor-interacting protein 3
31 32 33 34 35 36 37 38 39 40 41 42 43 44
2
ACS Paragon Plus Environment
Page 3 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
45
Abstract
46
It has emerged that hepatocyte necroptosis plays a critical role in chronic alcoholic liver disease (ALD).
47
Our previous study has identified that the beneficial therapeutic effect of curcumin on alcohol-caused
48
liver injury might be attributed to activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2),
49
whereas the role of curcumin in regulating necroptosis and the underlying mechanism remain to be
50
determined. We firstly found that chronic alcohol consumption triggered obvious hepatocyte
51
necroptosis, leading to increased expression of receptor-interacting protein 1, receptor-interacting
52
protein 3, high-mobility group box 1, and phosphorylated mixed lineage kinase domain-like in murine
53
livers. Curcumin dose-dependently ameliorated hepatocyte necroptosis and alleviated alcohol-caused
54
decrease in hepatic Nrf2 expression in alcoholic mice. Then Nrf2 shRNA lentivirus was introduced to
55
generate Nrf2-knockdown mice. Our results indicated that Nrf2 knockdown aggravated the effects of
56
alcohol on liver injury and necroptosis and even abrogated the inhibitory effect of curcumin on
57
necroptosis. Further, activated Nrf2 by curcumin inhibited p53 expression in both livers and cultured
58
hepatocytes under alcohol stimulation. The next in vitro experiments, similar to in vivo ones, revealed
59
that although Nrf2 knockdown abolished the suppression of curcumin on necroptosis of hepatocytes
60
exposed to ethanol, p53 siRNA could clearly rescued the relative effect of curcumin. In summary, for
61
the first time, we concluded that curcumin attenuated alcohol-induced hepatocyte necroptosis in a
62
Nrf2/p53-dependent mechanism. These findings make curcumin an excellent candidate for ALD
63
treatment and advance the understanding of ALD mechanisms associated with hepatocyte necroptosis.
64 65
Keywords
66
alcoholic liver disease; curcumin; necroptosis; Nrf2; p53
3
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
67
INTRODUCTION
68
Alcoholic liver disease (ALD) seriously threatens public health worldwide.1 In Asia, it carries a high
69
incidence among diverse liver diseases, ranking just behind virus hepatitis.2 Chronic alcohol
70
consumption damages hepatocytes and ultimately causes cell death. For long, only apoptosis was
71
considered as a sole model of programmed cell death in alcohol-exposed hepatocytes.3, 4 Recently
72
published studies highlighted an emerging role of hepatocyte necroptosis in facilitating ALD.5, 6 When
73
apoptosis was inhibited, cellular necroptosis would be enlarged which failed classical therapies to halt
74
cell loss and improve alcoholic liver injury.7
Page 4 of 34
75 76
Necroptotic cells would exhibit typical morphological changes, such as augmented cell volume,
77
disruption of plasma membrane, and cellular collapse.8 Necroptotic cells would release massive
78
intracellular contents named as damage-associated molecular patterns (DAMPs), including IL-1α and
79
high-mobility group box 1 (HMGB1), triggering inflammatory response.9-12 HMGB1 is a nuclear
80
protein secreted exclusively from necroptotic cells, which is generally used to distinguish necroptosis
81
from apoptosis. Necroptosis is a highly regulated process, and several unique signal molecules are
82
involved in executing necroptosis. Receptor-interacting protein 1 (RIP1) and receptor-interacting
83
protein 3 (RIP3) are defined as central contributors for initiating necroptosis. Activated RIP1 binds to
84
RIP3 and forms the necrosome complex.13 Formed necrosome recruits and activates mixed lineage
85
kinase domain-like (MLKL).14, 15 Phosphorylated MLKL then oligomerizes and binds to membrane
86
phospholipids, forming pores that cause necroptotic cell death. C-jun N-terminal kinase (JNK) is also a
87
downstream target gene of RIP3 which when phosphorylated induces mitochondrial oxidative stress
88
and fission and finally promotes necroptosis.16 Basic and clinical researches highlighted the execution
4
ACS Paragon Plus Environment
Page 5 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
89
of necroptosis in alcohol-related pathologies. Serum HMGB1 level, hepatic RIP3 expression and JNK
90
phosphorylation were significantly induced in alcohol-exposed small rodents and large mammals,
91
which resulted in severe liver inflammation and steatosis.17-19 RIP3 deficiency protected mice from
92
alcohol-caused liver injury, inflammation, and steatosis.12, 20, 21 Thus negative regulation of necroptosis
93
is anticipated to not only rescue hepatocyte fate but also improve inflammation and hepatic steatosis
94
induced by alcohol. Developing drugs targeting at necroptosis inhibition is urgently required.
95 96
Researches on pharmacological activities of curcumin have always been actively pursued.22 In our
97
previous study, we found that curcumin prevented ALD in rats by suppressing liver inflammation and
98
steatosis. Mechanistically, activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) was required
99
for curcumin to protect hepatocytes from ethanol-induced cell injury and lipid accumulation.23 Recently,
100
an original observation proposed that curcumin attenuated neuron necroptosis induced by iron overload
101
via inhibiting RIP1, laying the foundation for curcumin to modulate necroptosis.24 Nrf2 which when
102
activated could reduce HMGB1 release, implying that Nrf2 might serve as a modulator of
103
necroptosis.25-27 In present study, we hypothesized that curcumin could suppress alcohol-induced
104
hepatocyte necroptosis, in which activation of Nrf2 in hepatocytes could be a molecular basis. Both in
105
vivo and in vitro systems were introduced to confirm this hypothesis.
106 107
MATERIALS AND METHODS
108
Reagents and Antibodies
109
Curcumin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in
110
dimethylsulfoxide (DMSO; Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) in in vitro
5
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 6 of 34
111
experiments. Lentivirus vectors encoding negative control shRNA (NC shRNA) and Nrf2 shRNA were
112
constructed by Nanjing di rui biological technology Co., Ltd. (Nanjing, Jiangsu, China). Control
113
siRNA, Nrf2 siRNA, and p53 siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
114
USA). Primary antibody against RIP1 (17519-1-AP) was purchased from Proteintech Group, Inc.
115
(Rosemont, IL, USA). Primary antibodies against Nrf2 (sc-722), NAD(P)H: quinone oxidoreductase 1
116
(NQO1, sc-16464), RIP3 (sc-374639), p-JNK (sc-81502), JNK (sc-7345), and β-actin (sc-47778) were
117
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibodies against
118
HMGB1 (3935), p-MLKL (91689), MLKL (28640), and p53 (2524) as well as horseradish
119
peroxidase-conjugated secondary antibodies (7076 and 7074) were purchased from Cell Signaling
120
Technology (Danvers, MA, USA). The primers used in quantitative real-time polymerase chain
121
reaction (qRT-PCR) analyses were purchased from GenScript Co. Ltd. (Nanjing, Jiangsu, China).
122 123
Animal Models
124
Animals
125
All experimental procedures were approved by the institutional and local committee on the care and
126
use of animals of Nanjing University of Chinese Medicine (Nanjing, Jiangsu, China), and all animals
127
received human care in strict accordance with the National Institutes of Health guidelines. All animals
128
were kept in the specific pathogen free clean room under a controlled condition of 21-25 °C and a
129
12-h light/dark cycle and had free access to standard chow diet and water. This study was performed in
130
male ICR mice purchased from Nantong University (Nantong, Jiangsu, China), weighing 20-25 g.
131 132
Experimental Procedures
6
ACS Paragon Plus Environment
Page 7 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
133
Study I
134
In this experimental protocol, sixty mice were randomly divided into five groups (12 mice/group).
135
Group 1 was the vehicle control in which mice were not administrated with alcohol or curcumin but
136
normal saline (NS) orally and twice daily for four weeks. Group 2 was the model group in which mice
137
were orderly administrated with alcohol (56%, v/v, 10 mL/kg body weight) and NS without curcumin
138
by gavage every day for four weeks. Groups 3-5 were treatment groups in which mice were all
139
administrated with alcohol and respectively treated with curcumin that was suspended in sterile NS at
140
100, 200, and 400 mg/kg every day for four weeks.
141 142
Study II
143
In a second experimental protocol, sixty mice were randomly divided into five groups (12 mice/group).
144
Mice in groups 1-5 received corresponding treatments as follows: group 1, negative control (NC)
145
shRNA lentivirus and NS; group 2, NC shRNA lentivirus, alcohol, and NS; group 3, Nrf2 shRNA
146
lentivirus, alcohol, and NS; group 4, NC shRNA lentivirus, alcohol, and curcumin; group 5, Nrf2
147
shRNA lentivirus, alcohol, and curcumin. At day 1 of the four-week experiment, lentivirus with a titer
148
of 1 × 108 TU/mice was injected into caudal vein of mice.28-31 Alcohol (56%, v/v, 10 mL/kg body
149
weight) and curcumin (200 mg/kg body weight) were given every day by gavage.
150 151
Forty-eight hours after last administration, all mice were anesthetized by intraperitoneal injection with
152
pentobarbital (50 mg/kg). Blood was collected and livers were harvested. A small portion of each liver
153
was fixed in 10% neutral buffered formalin solution and embedded in paraffin for immunofluorescence
154
staining. The remaining liver was stored at liquid nitrogen for extraction of total proteins and RNA.
7
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
155
Cell Culture
156
Human hepatocyte LO2 cells were purchased from Cell Bank of Chinese Academy of Sciences
157
(Shanghai, China). Cells were cultured in Dulbecco’s modified eagle medium (DMEM; Invitrogen,
158
Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Invitrogen,
159
Merelbeke, Belgium), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 °C in a humidified
160
atmosphere of 95% air and 5% CO2.
Page 8 of 34
161 162
SiRNA Transfection
163
100 pmol Nrf2 siRNA or p53 siRNA was mixed with 150 µL medium without serum and antibiotics. 7
164
µL lipofectamine 2000 reagent (life technologies, New York, NY, USA) was mixed with 150 µL
165
medium. After incubation for 5 min at room temperature, both mixtures were gently mixed and
166
incubated for 10 min at room temperature. Then 700 µL medium without FBS and antibiotics were
167
added in and 1,000 µL transfection solution was prepared. Cells in 6-well plates were incubated with
168
transfection solution (1,000 µL/well) for 24 h at 37 °C. Control siRNA was used as a negative control.
169 170
Western Blot Analyses
171
Total proteins were extracted from liver tissues and hepatocytes using radioimmunoprecipitation assay
172
buffer supplemented with phenylmethylsufonyl fluoride and phosphatase inhibitor. Protein
173
concentrations were detected using a bicinchoninic acid assay kit (Pierce Biotechnology, Rockford, IL,
174
USA) according to the protocol from manufacturer. Total proteins (50 µg/sample) were separated by
175
sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred onto polyvinylidene
176
fluoride membranes. Then membranes were blocked with 5% skim milk in Tris-buffered saline
8
ACS Paragon Plus Environment
Page 9 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
177
containing 0.1% Tween 20 for 2 h. Target proteins were detected using corresponding primary
178
antibodies and secondary antibodies conjugated with horseradish peroxidase. Protein bands were
179
visualized using chemiluminescence reagent (Millipore, Burlington, MA, USA) and densitometrically
180
detected using Quantity Ones 4.4.1 (Bio-Rad Laboratories, Berkeley, CA, USA). β-Actin was probed
181
as an internal control. The relative abundance of target proteins was expressed as fold changes
182
compared with the control after normalization to β-actin or total protein.
183 184
RNA Extraction and QRT-PCR
185
Total RNA was extracted from liver tissues and hepatocytes using Trizol reagent according to the
186
protocol provided by manufacturer (Sigma-Aldrich, St. Louis, MO, USA). QRT-PCR was performed
187
according to our previous description.32 Glyceraldehyde phosphate dehydrogenase (GAPDH) was used
188
as an invariant control and mRNA levels were expressed as fold changes after normalization to
189
GAPDH. Primers used were listed in table 1 and 2.
190 191
Liver Histopathology and Immunofluorescence Staining
192
Transmission electron microscopy, H&E and immunofluorescence staining were performed as
193
previously described.23, 33
194 195
In situ hybridization (ISH)
196
ISH assays were performed with 5’digoxigenin (DIG)-labeled probe for Nrf2. The primer was used:
197
Nrf2, 5’-GCTGTGCTTTAGGTCCATTCTGTTTGACACTTCC-3’. Hybridization was carried out
198
according to the previous report.34
9
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 10 of 34
199
Biochemical Analyses
200
Serum was isolated from whole blood after centrifugation at 3600 rpm for 20 min and stored at −80 °C
201
for further analyses. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
202
levels were detected using corresponding commercial assay kits according to the protocols from
203
manufacturer (Nanjing Jiancheng Bioengeering Institute, Nanjing, Jiangsu, China). Absorbance values
204
were determined using a SPECTRAmaxTM microplate spectrophotometer (Molecular Devices,
205
Sunnyvale, CA, USA).
206 207
Enzyme-linked Immunosorbent Assay (ELISA)
208
The levels of IL-1α and HMGB1 in serum and cell culture supernatant were detected using
209
corresponding ELISA kits (Nanjing SenBeiJia Biological Technology Co., Ltd., Nanjing, Jiangsu,
210
China) under the direction of protocols from manufacturer.
211 212
MTT Assay
213
LO2 cells were seed in 96-well plates and cultured in complete medium for 24 h followed by
214
corresponding treatments. Cell viability was detected by MTT assay according to our precious
215
description.23
216 217
Statistical Analyses
218
All data were presented as mean ± SD, and results were analyzed using GraphPad Prism Software
219
Version 6.0 (GraphPad Software, La Jolla, CA). The significance of difference was determined by
220
one-way analysis of variance with the post hoc Dunnett’s test. Values of P < 0.05 were considered
10
ACS Paragon Plus Environment
Page 11 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
221
statistically significant.
222 223
RESULTS
224
Curcumin Prevents Necroptosis in Alcohol-Fed Mice. To investigate the action of curcumin on
225
alcohol-induced necroptosis, changes in DAMPs release to circular system were firstly measured for
226
their sensitive capacities of indicating necroptosis. Our results showed a clear increase in serum IL-1α
227
and HMGB1 levels in alcoholic mice but a dose-dependent decrease in curcumin-treated mice (Figure
228
1A,B). The mRNA and protein abundance of necroptosis markers in liver tissues, HMGB1, RIP1, and
229
RIP3, were upregulated under alcohol exposure but dose-dependently downregulated under curcumin
230
treatment. Alcohol stimulated the phosphorylation of MLKL and JNK while curcumin
231
dephosphorylated p-MLKL and p-JNK in a dose-dependent manner (Figure 1C,D). Taken together,
232
these data suggested that curcumin inhibited hepatic necroptosis in alcohol-preferring mice.
233 234
Curcumin Attenuates Alcoholic Liver Injury Dependent on Nrf2 Activation. Except for the
235
preferable anti-necroptosis effects, curcumin also abrogated alcohol-induced decrease in hepatic Nrf2
236
and NQO1 expression (Figure 1E). To explore the molecular basis underlying the anti-necroptosis
237
capacity of curcumin, Nrf2 was probed as a target for that Nrf2 was a vital modulator of necroptosis
238
and could be activated by curcumin as we previously reported. Nrf2-deficient animal model was
239
established on ICR mice using RNA interference technology. ISH analysis showed that Nrf2 shRNA
240
effectively silenced the mRNA expression of Nrf2 in mouse hepatocytes while no conspicuous change
241
in Nrf2 mRNA abundance was shown in NC shRNA-injected control mice. Curcumin rescued the
242
mRNA expression of Nrf2 in alcohol-treated mice, which was abrogated by Nrf2 shRNA (Figure 2A).
11
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 12 of 34
243
The protein abundance of hepatic Nrf2 and NQO1 in mice was consistently decreased by Nrf2 shRNA
244
but increased by curcumin (Figure 2B,C). Alcohol caused an increase in serum AST and ALT levels
245
and severe hepatohistological alternations. Curcumin alleviated alcohol-induced a sequence of
246
pathological changes. Notably, Nrf2 shRNA enhanced the toxic actions of alcohol, deteriorated hepatic
247
damage, and impaired improvement on alcohol-caused hepatotoxicity by curcumin (Figure 2D,E). In
248
summary, these data demonstrated that curcumin could activate hepatic Nrf2 which was a basis for
249
curcumin to prevent mice from chronic alcoholic liver injury.
250 251
Nrf2 Deficiency Blocks the Effective Improvement of Curcumin on Alcohol-Caused Hepatocyte
252
Necroptosis. Nrf2 function in the hepatoprotection against alcoholic necroptosis provided by curcumin
253
was further investigated. Curcumin treatment restrained alcohol-induced increase in release of IL-1α
254
and HMGB1. However, Nrf2 shRNA deteriorated alcohol effect and further repressed curcumin
255
function (Figure 3A,B). Transmission electron microscopy vividly concretized and visualized
256
hepatocyte necroptosis. Normal hepatocytes displayed regular cellular morphology with intact
257
cytoplasmic membranes, while necroptotic hepatocytes in alcohol-exposed wild-type or
258
Nrf2-knockdown mice exhibited discontinuous cytoplasmic membranes, edema cytoplasm, and
259
swollen mitochondria. Notably, hepatocytes undergoing necroptosis displayed unique ultrastructural
260
modifications of nucleus, including dilatation of nuclear membranes, condensation of chromatin into
261
small, irregular, and circumscribed patches, and chromatin margination. Curcumin transformed cellular
262
morphology and inhibited cell necroptosis in alcohol-administrated wild-type mice but not
263
Nrf2-knockdown mice (Figure 3C). Markers and signaling transduction of necroptosis were also
264
measured. Results showed that the Nrf2 shRNA strengthened alcohol-induced increase in the
12
ACS Paragon Plus Environment
Page 13 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
265
expression of hepatic HMGB1, RIP1, and RIP3 at both transcriptional and translational levels and
266
further enhanced phosphorylation of MLKL and JNK. Although curcumin had significant inhibitory
267
effects on these necroptosis-related markers, Nrf2 shRNA obviously abolished the effects of curcumin
268
(Figure 3D,E). Immunofluorescence staining for RIP1, RIP3, and p-JNK further validated the results of
269
western blot (Figure 3F-H). Collectively, these data implied that inhibition of alcohol-induced
270
hepatocyte necroptosis by curcumin was attributed to activation of Nrf2.
271 272
Curcumin Suppresses p53 Expression Mediated by Activation of Nrf2. Given that Nrf2-mediated
273
control of necroptosis might be attributed to regulating p53, we next investigated whether curcumin
274
regulated p53 through activating Nrf2. Results from in vivo experiments showed that compared with
275
control, alcohol administration induced hepatic p53 expression, which was further strengthened by
276
Nrf2 shRNA. Curcumin inhibited hepatic p53 expression in alcohol-fed wild-type mice but not
277
Nrf2-knockdown mice (Figure 4A-C). Then human hepatocyte LO2 cells treated with 100 mM
278
ethanol for 24 hours were applied to establish an in vitro model of alcoholic liver injury. Nrf2 siRNA
279
efficiently inhibited cellular Nrf2 and downstream gene NQO1 expression, suggesting that the
280
transfection was successful (Figure 4D). Results from in vitro investigations exhibited parallel changes
281
in p53 expression (Figure 4E-G). Altogether, these findings implied that inhibition of ethanol-induced
282
necroptosis by curcumin might be associated with its modulation on Nrf2/p53 signaling pathway.
283 284
Curcumin Inhibits Ethanol-Induced Hepatocyte Necroptosis through Nrf2/p53 Pathway. To
285
provide a deeper mechanistic insight into the protection of curcumin against ethanol-induced
286
hepatocyte necroptosis, the role of Nrf2/p53 pathway was explored. P53 siRNA obviously reduced the
13
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 14 of 34
287
expression of p53 in LO2 cells, suggesting a successful gene transfection (Figure 5A). Results of MTT
288
assay showed that hepatocyte viability was inhibited by ethanol exposure but regained by curcumin.
289
The cytoprotective effect of curcumin was cancelled in Nrf2-knockdown hepatocytes but rescued in
290
p53 siRNA-administrated Nrf2-knockdown hepatocytes (Figure 5B). Hepatocytes incubated with
291
ethanol underwent necroptosis, released a large amount of HMGB1 into culture medium. Curcumin not
292
only decreased HMGB1 release but also diminished the expression of intracellular HMGB1, RIP1,
293
RIP3, p-MLKL, and p-JNK. Nrf2 siRNA abrogated the effects of curcumin. However, p53 siRNA
294
neutralized the impact of Nrf2 siRNA and restored the pharmacological activity of curcumin, resulting
295
in reduction of necroptosis-related markers (Figure 5C-E). Immunofluorescence staining for RIP1,
296
RIP3, and p-JNK further enhanced the results above (Figure 5F-H). In brief, these data consistently
297
indicated that curucmin inhibited ethanol-triggered hepatocyte necroptosis in a Nrf2/p53
298
pathway-dependent mechanism.
299 300
DISCUSSION
301
Many studies and ours have highlighted the curative effect of curcumin on ALD and preliminarily
302
revealed the foundational mechanisms. We observed that curcumin alleviated alcohol-induced lipid
303
accumulation in both rat livers and human hepatocytes, wherein Nrf2 might be a molecular target for
304
curcumin to regulate lipid metabolism.23 In this work, we for the first time provided compelling
305
evidence that curcumin inhibited alcohol-triggered hepatocyte necroptosis. Mechanistically, Nrf2/p53
306
pathway might be an important mediator for curcumin to alleviate hepatocyte necroptosis.
307 308
We initially tested whether curcumin affected alcohol-induced hepatocyte necroptosis in mouse livers.
14
ACS Paragon Plus Environment
Page 15 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
309
ALD model was established in rodents as our previous description.23, 35, 36 Alcohol would cause
310
hepatocyte injury via facilitating necroptosis characterized by released HMGB1 and increased RIP3.20,
311
37, 38
312
alcohol, suggesting that alcohol stimulated HMGB1 secretion. The mRNA and protein expression of
313
HMGB1 in mouse livers were also upregulated under alcohol exposure, suggesting that HMGB1 was
314
activated as a nuclear factor. RIP3 expression was obviously increased in alcoholic mouse livers, which
315
was accordant to a previous study.20 These results were consistent with prior evidence that HMGB1 and
316
RIP3 were involved in alcohol-induced liver injury.39, 40 Of importance was the fact that curcumin
317
simultaneously reduced HMGB1 release and decreased the expression of HMGB1 and RIP3. Notably,
318
hepatic RIP1 expression was found to be induced by alcohol, which was inconsistent with a prior study
319
that RIP1 level was not significantly altered by alcohol.20 We proposed that varieties of feeding patterns,
320
mouse strains, duration of alcohol exposure, and animal gender among experiments caused diverse
321
degrees of liver damage, which could explain this difference.41 Phosphorylation of MLKL is the
322
necrosome core machinery which leads to the formation of autologous oligomers that is essential and
323
sufficient for triggering necroptosis.42-44 Obviously, alcohol enhanced phosphorylation of MLKL,
324
which could be inhibited by curcumin. A previous study established a close correlation between JNK
325
activation and alcohol-induced hepatic steatosis and oxidative stress.45 Activation of JNK signaling is
326
an alternative way for RIP3 to execute necroptosis.20 Thus the activated state of JNK was investigated.
327
Results showed that curcumin could dose-dependently suppress alcohol-induced phosphorylation of
328
JNK. The present study highlighted the potential of curcumin to target necroptosis to intervene
329
alcoholic liver injury.
In this study, in analog to others, we observed an increase in serum HMGB1 level caused by
330
15
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 16 of 34
331
To further explore whether Nrf2 activation was implicated in pharmacological function of curcumin,
332
Nrf2 shRNA-mediated knockdown mice was generated according to our previous study with
333
modification.31 Hepatic Nrf2 expression was significantly suppressed by Nrf2 shRNA. NQO1, a Nrf2
334
downstream-regulated gene, was also inhibited, revealing an impaired Nrf2 activity in
335
Nrf2-knockdown mice. Our previous work indicated that curcumin significantly relieved inflammatory
336
response in rats exposed to chronic plus binge alcohol.23 In this study, serum biomarkers of liver injury
337
and hepatic microstructure were firstly measured to evaluate the model and drug efficacy. Results
338
showed that alcohol-induced liver injury was established in mice and aggravated by Nrf2 shRNA.
339
Curcumin could notably alleviate liver injury, which could be abolished by Nrf2 shRNA. These data
340
suggested that Nrf2 activation was required for curcumin to prevent alcohol-caused liver injury, further
341
expanding our previous in vivo findings.
342 343
We subsequently investigated whether activated Nrf2 mediated the inhibitory effect of curcumin on
344
necroptosis. Previous studies revealed that HMGB1 release could be inhibited by active compounds via
345
a Nrf2-dependent manner, which could support the current speculation that Nrf2 was a critical regulator
346
of necroptosis.25, 46-49 We found that Nrf2 shRNA stimulated the alcohol action and enlarged its
347
induction of HMGB1. Curcumin suppressed HMGB1 expression and secretion in a Nrf2-dependent
348
mechanism. Further, the inhibitory effect of curcumin on necroptosis-related regulatory factors was
349
abolished by Nrf2 shRNA. These discoveries uncovered the pivotal role of Nrf2 in regulation of
350
necroptosis and Nrf2 could be a target molecular for developing agents to treat necroptosis in alcoholic
351
liver injury.
352
16
ACS Paragon Plus Environment
Page 17 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
353
Next investigations were focused on exploring which factor mediated the Nrf2-dependent regulation of
354
necroptosis by curcumin. For a long time, it has been pursued by researchers that whether Nrf2 and p53
355
cooperatively controlled cell survival and death.50-52 Nuclear transcription factor p53 used to be
356
recognized as a routine controller of apoptosis and necrosis which would increase when liver was
357
damaged by alcohol consumption.53, 54 Newly researches uncovered its rising role in triggering
358
necroptosis. Indirect evidence suggested that p53 activation stimulated HMGB1 release.55-58 Direct
359
evidence confirmed that p53-cathepsin axis cooperated with ROS to activate programmed necrotic
360
death upon DNA damage, while p53 stable knockdown alleviated salinomycin-induced programmed
361
necrosis in glioma cells.55, 59 Based on these findings, we speculated that Nrf2/p53 pathway could be
362
involved in curcumin-based inhibition of hepatocyte necroptosis. By using RNA interference
363
technology in in vivo and in vitro systems, we observed that curcumin negatively regulated p53
364
expression via modulating Nrf2, suggesting a modulation by curcumin of Nrf2/p53 pathway. Herein,
365
immortalized human hepatocyte LO2 cells were incubated with 100 mM ethanol for 24 hours to
366
establish an in vitro model of ALD as described in our previous study.23 LO2 cells were derived from
367
primary normal human hepatocytes and maintained the biological features and ultrastructures of
368
normal adult hepatocytes. After stable transfection with human telomerase reverse transcriptase gene,
369
LO2 cells were immortalized and widely used as an in vitro model of liver tissues for studying the
370
pathophysiology of hepatocytes.60 And our findings showed a consolidated correlation between Nrf2
371
and p53, although how it worked was still unclear and needed exploration. Whether the pathway was
372
involved in the regulation of ethanol-stimulated hepatocyte necroptosis by curcumin was further
373
explored. We noticed that p53 siRNA exerted antagonistic action against Nrf2 siRNA, resulting in a
374
restoration of hepatocyte viability against alcoholic hepatotoxicity. P53 siRNA also restored the
17
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 18 of 34
375
inhibitory effect of curcumin on necroptosis in ethanol-stimulated Nrf2-knockdown hepatocytes. All
376
these discoveries, including ours, consolidated the central impact of p53 in the execution of necroptosis.
377
Our study further demonstrated that p53 suppression contributed to Nrf2 activation-mediated control of
378
hepatocyte necroptosis by curcumin.
379 380
In summary, our work demonstrated that curcumin improved ethanol-induced hepatocyte necroptosis in
381
vivo and in vitro. Mechanistically, modulation of Nrf2/p53 pathway was a molecular basis for curcumin
382
to inhibit hepatocyte necroptosis. For the first time, our current discoveries not only indicated that
383
inhibition of hepoatocyte necroptosis could be a promising target for curcumin to attenuate
384
alcohol-induced liver injury but also provided insightful views of molecular mechanisms involved,
385
which pushed forward the progress of developing curcumin into a candidate agent for ALD treatment.
386 387
CONFLICT OF INTEREST
388
The authors declare that there are no conflicts of interest.
389 390
ACKNOWLEDGMENTS
391
This work was supported by the National Natural Science Foundation of China (81270514, 31401210,
392
31571455), A Project Funded by the Priority Academic Program Development of Jiangsu Higher
393
Education Institutions, the Youth Natural Science Foundation of Jiangsu Province (BK20140955), 2013
394
Program for Excellent Scientific and Technological Innovation Team of Jiangsu Higher Education, the
395
Youth Natural Science Foundation of Nanjing University of Chinese Medicine (13XZR20), the Natural
396
Science Research General Program of Jiangsu Higher Education Institutions (14KJB310011), and 2015
18
ACS Paragon Plus Environment
Page 19 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
397
Program for Graduate Scientific Innovation of Jiangsu Higher Education Institutions (KYLX15_0999).
398 399
REFERENCES
400
(1) Sugimoto, K.; Takei, Y.
401
official journal of the Japan Society of Hepatology 2016.
402
(2) Schwartz, J. M.; Reinus, J. F.
403
Liver Dis. 2012, 16, 659-666.
404
(3) Nagata, K.; Suzuki, H.; Sakaguchi, S.
405
progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J. Toxicol. Sci. 2007, 32,
406
453-468.
407
(4) Malhi, H.; Guicciardi, M. E.; Gores, G. J.
408
Rev. 2010, 90, 1165-1194.
409
(5) Shulga, N.; Pastorino, J. G.
410
exposure to fructose and ethanol. J. Cell Sci. 2014, 127, 896-907.
411
(6) Barnes, M. A.; Roychowdhury, S.; Nagy, L. E.
412
disease: role of cytochrome P4502E1. Redox Biol 2014, 2, 929-935.
413
(7) Roychowdhury, S.; Chiang, D. J.; Mandal, P.; McMullen, M. R.; Liu, X.; Cohen, J. I.; Pollard, J.;
414
Feldstein, A. E.; Nagy, L. E.
415
of early markers of CCl4 -induced fibrosis but not steatosis or inflammation. Alcohol. Clin. Exp. Res.
416
2012, 36, 1139-1147.
417
(8) Vanden Berghe, T.; Vanlangenakker, N.; Parthoens, E.; Deckers, W.; Devos, M.; Festjens, N.;
418
Guerin, C. J.; Brunk, U. T.; Declercq, W.; Vandenabeele, P.
Pathogenesis of alcoholic liver disease. Hepatology research : the
Prevalence and natural history of alcoholic liver disease. Clin.
Common pathogenic mechanism in development
Hepatocyte death: a clear and present danger. Physiol.
Mitoneet mediates TNFalpha-induced necroptosis promoted by
Innate immunity and cell death in alcoholic liver
Inhibition of apoptosis protects mice from ethanol-mediated acceleration
Necroptosis, necrosis and secondary
19
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 20 of 34
419
necrosis converge on similar cellular disintegration features. Cell Death Differ. 2010, 17, 922-930.
420
(9) Krysko, D. V.; Agostinis, P.; Krysko, O.; Garg, A. D.; Bachert, C.; Lambrecht, B. N.;
421
Vandenabeele, P.
422
in inflammation. Trends in immunology 2011, 32, 157-164.
423
(10) Kaczmarek, A.; Vandenabeele, P.; Krysko, D. V.
424
molecular patterns and its physiological relevance. Immunity 2013, 38, 209-223.
425
(11) Kang, T. B.; Yang, S. H.; Toth, B.; Kovalenko, A.; Wallach, D.
426
RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 2013, 38, 27-40.
427
(12) Kang, T. B.; Yang, S. H.; Toth, B.; Kovalenko, A.; Wallach, D.
428
inflammasome by proteins that signal for necroptosis. Methods in enzymology 2014, 545, 67-81.
429
(13) Saeed, W. K.; Jun, D. W.
430
journal of gastroenterology 2014, 20, 12526-12532.
431
(14) Sun, L.; Wang, H.; Wang, Z.; He, S.; Chen, S.; Liao, D.; Wang, L.; Yan, J.; Liu, W.; Lei, X.; Wang,
432
X.
433
Cell 2012, 148, 213-227.
434
(15) Zhao, J.; Jitkaew, S.; Cai, Z.; Choksi, S.; Li, Q.; Luo, J.; Liu, Z. G.
435
domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis.
436
Proceedings of the National Academy of Sciences of the United States of America 2012, 109,
437
5322-5327.
438
(16) Ramachandran, A.; McGill, M. R.; Xie, Y.; Ni, H. M.; Ding, W. X.; Jaeschke, H.
439
interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis
440
in mice. Hepatology 2013, 58, 2099-2108.
Emerging role of damage-associated molecular patterns derived from mitochondria
Necroptosis: the release of damage-associated
Caspase-8 blocks kinase
Activation of the NLRP3
Necroptosis: an emerging type of cell death in liver diseases. World
Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase.
Mixed lineage kinase
Receptor
20
ACS Paragon Plus Environment
Page 21 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
441
(17) Nishitani, Y.; Matsumoto, H.
Ethanol rapidly causes activation of JNK associated with ER stress
442
under inhibition of ADH. FEBS letters 2006, 580, 9-14.
443
(18) Yang, L.; Wu, D.; Wang, X.; Cederbaum, A. I.
444
autophagy in acute alcohol-induced fatty liver. Free radical biology & medicine 2012, 53, 1170-1180.
445
(19) Wang, X.; Bu, H. F.; Zhong, W.; Asai, A.; Zhou, Z.; Tan, X. D.
446
involved in the mechanism underlying alcohol-induced impairment of macrophage efferocytosis. Mol
447
Med 2013, 19, 170-182.
448
(20) Roychowdhury, S.; McMullen, M. R.; Pisano, S. G.; Liu, X.; Nagy, L. E.
449
interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 2013, 57, 1773-1783.
450
(21) Zhang, J.; Zhang, Y.; Xiao, F.; Liu, Y.; Wang, J.; Gao, H.; Rong, S.; Yao, Y.; Li, J.; Xu, G.
451
peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents NF-kappaB activation
452
in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300
453
pathway. Biochemical pharmacology 2016, 101, 100-111.
454
(22) Pulido-Moran, M.; Moreno-Fernandez, J.; Ramirez-Tortosa, C.; Ramirez-Tortosa, M.
455
and Health. Molecules 2016, 21.
456
(23) Lu, C.; Zhang, F.; Xu, W.; Wu, X.; Lian, N.; Jin, H.; Chen, Q.; Chen, L.; Shao, J.; Wu, L.; Lu, Y.;
457
Zheng, S.
458
signaling in hepatocytes. IUBMB life 2015, 67, 645-658.
459
(24) Dai, M. C.; Zhong, Z. H.; Sun, Y. H.; Sun, Q. F.; Wang, Y. T.; Yang, G. Y.; Bian, L. G.
460
protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosis.
461
Neurosci. Lett. 2013, 536, 41-46.
462
(25) Wang, J.; Hu, X.; Xie, J.; Xu, W.; Jiang, H.
Cytochrome P4502E1, oxidative stress, JNK, and
MFG-E8 and HMGB1 are
Absence of receptor
The
Curcumin
Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR
Curcumin
Beta-1-adrenergic receptors mediate
21
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 22 of 34
463
Nrf2-HO-1-HMGB1 axis regulation to attenuate hypoxia/reoxygenation-induced cardiomyocytes
464
injury in vitro. Cell. Physiol. Biochem. 2015, 35, 767-777.
465
(26) Kim, S. R.; Ha, Y. M.; Kim, Y. M.; Park, E. J.; Kim, J. W.; Park, S. W.; Kim, H. J.; Chung, H. T.;
466
Chang, K. C.
467
cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals. Biochem.
468
Pharmacol. 2015, 95, 279-289.
469
(27) Tan, Y.; Wang, Q.; She, Y.; Bi, X.; Zhao, B.
470
activation of the Nrf2/HO-1 pathway and NF-kappaB suppression. The journal of trauma and acute
471
care surgery 2015, 78, 784-792.
472
(28) Liu, Z.; Wang, J.; Huang, X.; Li, Z.; Liu, P.
473
dysfunction and atherosclerosis in apolipoprotein E-deficient mice. Translational research : the journal
474
of laboratory and clinical medicine 2016.
475
(29) Zhang, W.; Niu, M.; Yan, K.; Zhai, X.; Zhou, Q.; Zhang, L.; Zhou, Y.
476
with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c
477
expression of rat hepatic stellate cells. The international journal of biochemistry & cell biology 2013,
478
45, 736-744.
479
(30) Zhai, X.; Yan, K.; Fan, J.; Niu, M.; Zhou, Q.; Zhou, Y.; Chen, H.
480
contributes to the effects of leptin on SREBP-1c expression in rat hepatic stellate cells and liver fibrosis.
481
British journal of pharmacology 2013, 169, 197-212.
482
(31) Lu, C.; Xu, W.; Zhang, F.; Shao, J.; Zheng, S.
483
effects of ligustrazine on hepatic fibrosis by targeting hepatic stellate cell transdifferentiation.
484
Toxicology 2016, 365, 35-47.
Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7
Ketamine reduces LPS-induced HMGB1 via
Deletion of sirtuin 6 accelerates endothelial
Stat3 pathway correlates
The beta-catenin pathway
Nrf2 knockdown attenuates the ameliorative
22
ACS Paragon Plus Environment
Page 23 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
485
(32) Zhang, F.; Zhang, Z.; Chen, L.; Kong, D.; Zhang, X.; Lu, C.; Lu, Y.; Zheng, S.
Curcumin
486
attenuates angiogenesis in liver fibrosis and inhibits angiogenic properties of hepatic stellate cells.
487
Journal of cellular and molecular medicine 2014, 18, 1392-1406.
488
(33) Bao, C.; Shao, Y.; Li, X.
489
Ultrastructural pathology 2014, 38, 217-223.
490
(34) Zhang, L.; Xiang, Z. L.; Zeng, Z. C.; Fan, J.; Tang, Z. Y.; Zhao, X. M.
491
prediction model for lymph node metastasis in hepatocellular carcinoma. Oncotarget 2016, 7,
492
3587-3598.
493
(35) Lu, C.; Xu, W.; Zhang, F.; Jin, H.; Chen, Q.; Chen, L.; Shao, J.; Wu, L.; Lu, Y.; Zheng, S.
494
Ligustrazine prevents alcohol-induced liver injury by attenuating hepatic steatosis and oxidative stress.
495
Int. Immunopharmacol. 2015, 29, 613-621.
496
(36) Chen, L. Y.; Chen, Q.; Cheng, Y. F.; Jin, H. H.; Kong, D. S.; Zhang, F.; Wu, L.; Shao, J. J.; Zheng,
497
S. Z.
498
apoptosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2016, 79, 35-43.
499
(37) Shulga, N.; Pastorino, J. G.
500
exposure to fructose and ethanol. Journal of cell science 2014, 127, 896-907.
501
(38) Ge, X.; Antoine, D. J.; Lu, Y.; Arriazu, E.; Leung, T. M.; Klepper, A. L.; Branch, A. D.; Fiel, M. I.;
502
Nieto, N.
503
disease (ALD). The Journal of biological chemistry 2014, 289, 22672-22691.
504
(39) Wang, X.; Bu, H. F.; Zhong, W.; Asai, A.; Zhou, Z.; Tan, X. D.
505
involved in the mechanism underlying alcohol-induced impairment of macrophage efferocytosis. Mol.
506
Med. 2013, 19, 170-182.
Hepatocyte necroptosis induced by ischemic acute kidney injury in rats.
A microRNA-based
Diallyl trisulfide attenuates ethanol-induced hepatic steatosis by inhibiting oxidative stress and
Mitoneet mediates TNFalpha-induced necroptosis promoted by
High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver
MFG-E8 and HMGB1 are
23
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 24 of 34
507
(40) Ge, X.; Antoine, D. J.; Lu, Y.; Arriazu, E.; Leung, T. M.; Klepper, A. L.; Branch, A. D.; Fiel, M. I.;
508
Nieto, N.
509
disease (ALD). J. Biol. Chem. 2014, 289, 22672-22691.
510
(41) Eagon, P. K.
511
gastroenterology 2010, 16, 1377-1384.
512
(42) Cai, Z.; Jitkaew, S.; Zhao, J.; Chiang, H. C.; Choksi, S.; Liu, J.; Ward, Y.; Wu, L. G.; Liu, Z. G.
513
Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis.
514
Nat. Cell Biol. 2014, 16, 55-65.
515
(43) Chen, X.; Li, W.; Ren, J.; Huang, D.; He, W. T.; Song, Y.; Yang, C.; Zheng, X.; Chen, P.; Han, J.
516
Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell
517
death. Cell Res. 2014, 24, 105-121.
518
(44) Wang, H.; Sun, L.; Su, L.; Rizo, J.; Liu, L.; Wang, L. F.; Wang, F. S.; Wang, X.
519
kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3.
520
Mol. Cell 2014, 54, 133-146.
521
(45) Yang, L.; Wu, D.; Wang, X.; Cederbaum, A. I.
522
autophagy in acute alcohol-induced fatty liver. Free Radic. Biol. Med. 2012, 53, 1170-1180.
523
(46) Bray, K.; Mathew, R.; Lau, A.; Kamphorst, J. J.; Fan, J.; Chen, J.; Chen, H. Y.; Ghavami, A.; Stein,
524
M.; DiPaola, R. S.; Zhang, D.; Rabinowitz, J. D.; White, E.
525
kinase-dependent necrosis enabling survival to mTOR inhibition. PloS one 2012, 7, e41831.
526
(47) Dong, W. W.; Liu, Y. J.; Lv, Z.; Mao, Y. F.; Wang, Y. W.; Zhu, X. Y.; Jiang, L.
527
barrier protection by resveratrol involves inhibition of HMGB1 release and HMGB1-induced
528
mitochondrial oxidative damage via an Nrf2-dependent mechanism. Free radical biology & medicine
High mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver
Alcoholic liver injury: influence of gender and hormones. World journal of
Mixed lineage
Cytochrome P4502E1, oxidative stress, JNK, and
Autophagy suppresses RIP
Lung endothelial
24
ACS Paragon Plus Environment
Page 25 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
529
2015, 88, 404-416.
530
(48) Kim, S. R.; Ha, Y. M.; Kim, Y. M.; Park, E. J.; Kim, J. W.; Park, S. W.; Kim, H. J.; Chung, H. T.;
531
Chang, K. C.
532
cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals. Biochemical
533
pharmacology 2015, 95, 279-289.
534
(49) Kim, Y. M.; Kim, H. J.; Chang, K. C.
535
lipopolysaccharide-activated RAW 264.7 cells and endotoxemic mice by p38/Nrf2-dependent induction
536
of HO-1. International immunopharmacology 2015, 26, 112-118.
537
(50) Bui, C. B.; Shin, J.
538
p53-dependent mitotic catastrophe. Biochem. Biophys. Res. Commun. 2011, 412, 347-352.
539
(51) You, A.; Nam, C. W.; Wakabayashi, N.; Yamamoto, M.; Kensler, T. W.; Kwak, M. K.
540
Transcription factor Nrf2 maintains the basal expression of Mdm2: An implication of the regulation of
541
p53 signaling by Nrf2. Arch. Biochem. Biophys. 2011, 507, 356-364.
542
(52) Chen, W.; Jiang, T.; Wang, H.; Tao, S.; Lau, A.; Fang, D.; Zhang, D. D.
543
p53-mediated control of cell survival and death? Antioxidants & redox signaling 2012, 17, 1670-1675.
544
(53) Yokoyama, A.; Omori, T.; Tanaka, Y.; Yokoyama, T.; Sugiura, H.; Mizukami, T.; Matsushita, S.;
545
Higuchi, S.; Maruyama, K.; Ishii, H.; Hibi, T.
546
aldehyde dehydrogenase-2 genotype in Japanese alcoholic men with early esophageal squamous cell
547
carcinoma. Cancer letters 2007, 247, 243-252.
548
(54) Yokoyama, A.; Tanaka, Y.; Yokoyama, T.; Mizukami, T.; Matsui, T.; Maruyama, K.; Omori, T.
549
p53 protein accumulation, iodine-unstained lesions, and alcohol dehydrogenase-1B and aldehyde
550
dehydrogenase-2 genotypes in Japanese alcoholic men with esophageal dysplasia. Cancer letters 2011,
Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7
Glycyrrhizin reduces HMGB1 secretion in
Persistent expression of Nqo1 by p62-mediated Nrf2 activation facilitates
Does Nrf2 contribute to
p53 Protein accumulation, cancer multiplicity, and
25
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 26 of 34
551
308, 112-117.
552
(55) Tu, H. C.; Ren, D.; Wang, G. X.; Chen, D. Y.; Westergard, T. D.; Kim, H.; Sasagawa, S.; Hsieh, J.
553
J.; Cheng, E. H.
554
upon DNA damage. Proceedings of the National Academy of Sciences of the United States of America
555
2009, 106, 1093-1098.
556
(56) Huang, H.; Xiao, T.; He, L.; Ji, H.; Liu, X. Y.
557
induces both apoptosis and necroptosis in cancer cells. Acta biochimica et biophysica Sinica 2012, 44,
558
737-745.
559
(57) Yan, H. X.; Wu, H. P.; Zhang, H. L.; Ashton, C.; Tong, C.; Wu, H.; Qian, Q. J.; Wang, H. Y.; Ying,
560
Q. L.
561
Journal of hepatology 2013, 59, 762-768.
562
(58) Davalos, A. R.; Kawahara, M.; Malhotra, G. K.; Schaum, N.; Huang, J.; Ved, U.; Beausejour, C.
563
M.; Coppe, J. P.; Rodier, F.; Campisi, J.
564
mediator of senescent phenotypes. The Journal of cell biology 2013, 201, 613-629.
565
(59) Qin, L. S.; Jia, P. F.; Zhang, Z. Q.; Zhang, S. M.
566
salinomycin-induced glioma cell necrosis. Journal of experimental & clinical cancer research : CR
567
2015, 34, 57.
568
(60) Cheng, B.; Zheng, Y.; Guo, X.; Wang, Y.; Liu, C.
569
features and expressions of DNA repair enzymes in LO2 cells. Liver international : official journal of
570
the International Association for the Study of the Liver 2010, 30, 319-326.
The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death
Interferon-beta-armed oncolytic adenovirus
p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release.
p53-dependent release of Alarmin HMGB1 is a central
ROS-p53-cyclophilin-D signaling mediates
Hepatitis B viral X protein alters the biological
571 572 573 26
ACS Paragon Plus Environment
Page 27 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
574
Table 1. Primers used for determination of mRNA expression levels in frozen mice liver tissues Gene
Forward primer
Reverse primer
SREBP-1c
5’-ACGGAGCCATGGATTGCACA-3’
5’-AAGGGTGCAGGTGTCACCTT-3’
PPAR-α
5’-TACGGTGTGTATGAAGCCATCTT-3’
5’-GCCGTACGCGATCAGCAT-3’
HMGB1
5’-CCATTGGTGATGTTGCAAAG-3’
5’-CTTTTTCGCTGCATCAGGTT-3’
RIP1
5’-CAGCCAAATCAAAGTGC-3’
5’-GGTGTTAGCGAAGACGG-3’
RIP3
5’-GGGACCTCAAGCCCTCTAAC-3’
5’-CTGGGTCCAAGTACGCTAGG-3’
p53
5’-GTAGGAAGGCGCGTGGTAG-3’
5’-CAGTTACAGGAACCCCGAG-3’
GAPDH
5’-CTATGACCACAGTCCATGC-3’
5’-CACATTGGGGGTAGGAACAC-3’
575 576 577 578 579 580 581 582 583 584 585 586 587
27
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
588
Page 28 of 34
Table 2. Primers used for determination of mRNA expression levels in LO2 hepatocytes Gene
Forward primer
Reverse primer
p53
5’-CAGCACATGACGGAGGTTGT-3’
5’-TCATCCAAATACTCCACACGC-3’
HMGB1
5’-AAGTGAGAGCCAGACGGG-3’
5’-TCCTTTGCCCATGTTTAATTATTTTC-3’
RIP1
5’-CTCCTTGCCACCAACAGATG-3’
5’-TCCGTCAGACTAGTGGTATTATCAAAG-3’
RIP3
5’-CTCTCTGCGAAAGGACCAAG-3’
5’-TCGTAGCCCCACTTCCTATG-3’
GAPDH
5’-CCAACCGCGAGAAGATGA-3’
5’-CCAGAGGCGTACAGGGATAG-3’
589
28
ACS Paragon Plus Environment
Page 29 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 1. Curcumin prevents necroptosis in alcohol-fed mice. (A and B) Levels of serum IL-1α and HMGB1, n=10. (C) The mRNA expression of HMGB1, RIP1, and RIP3 in liver tissues, n=3. (D and E) The protein expression of HMGB1, RIP1, RIP3, p-MLKL, MLKL, p-JNK, JNK, Nrf2, and NQO1 in liver tissues, n=3. For the statistics of each panel in this figure, data are expressed as mean ± SD, ##P < 0.01 and ###P < 0.001 compared with group 1, *P < 0.05, **P < 0.01, and ***P < 0.001 compared with group 2. 75x47mm (600 x 600 DPI)
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Figure 2. Curcumin attenuates alcoholic liver injury dependent on Nrf2 activation. (A) ISH of Nrf2 in murine livers (original magnification, 20×), n=6. (B) The protein expression of Nrf2 and NQO1 in liver tissues, n=3. (C) Immunofluorescence staining for Nrf2 in liver sections (original magnification, 20×), n=6. (D) Serum AST and ALT levels, n=10. (E) H&E staining of liver sections (original magnification, 20×), n=6. For the statistics of each panel in this figure, data are expressed as mean ± SD, ##P < 0.01 and ###P < 0.001 compared with group 1, **P < 0.01 compared with group 2, $P < 0.05 and $$P < 0.01 compared with group 4. 85x62mm (600 x 600 DPI)
ACS Paragon Plus Environment
Page 30 of 34
Page 31 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 3. Nrf2 deficiency blocks the effective improvement of curcumin on alcohol-caused hepatocyte necroptosis. (A and B) Levels of serum IL-1α and HMGB1, n=10. (C) Transmission electron microscopy of livers, n=6. In hepatocytes (H), swollen mitochondria (M) are indicated by black arrows. Condensed and marginated chromatins in nuclei (N) are indicated by white arrows. (D) The mRNA expression of HMGB1, RIP1, RIP3 in liver tissues, n=3. (E) The protein expression of HMGB1, RIP1, RIP3, p-MLKL, MLKL, p-JNK, and JNK in liver tissues, n=3. (F-H) Immunofluorescence staining for RIP1, RIP3, and p-JNK in livers (original magnification, 40×) , n=6. For the statistics of each panel in this figure, data are expressed as mean ± SD, ##P < 0.01 and ###P < 0.001 compared with group 1, *P < 0.05 and **P < 0.01 compared with group 2, $P < 0.05 and $$P < 0.01 versus group 4. 131x136mm (600 x 600 DPI)
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Figure 4. Curcumin suppresses p53 expression mediated by activation of Nrf2. (A) The mRNA expression of hepatic p53, n=3. (B) The protein expression of hepatic p53, n=3. (C) Immunofluorescence staining for p53 in livers (original magnification, 40×), n=6. For the statistics of the panels above, data are expressed as mean ± SD. ##P < 0.01 and ###P < 0.001 compared with group 1, **P < 0.01 compared with group 2, $$P < 0.01 compared with group 4. (D) Human hepatocyte LO2 cells were treated with control siRNA or Nrf2 siRNA for 24 h. Western blot analyses of Nrf2 and NQO1 expression in hepatocytes. For this panel, data are expressed as mean ± SD, ***P < 0.001 versus blank control. LO2 cells were treated with DMSO (0.02%, w/v) and/or ethanol and/or curcumin and/or Nrf2 siRNA at the indicated doses for 24 h. (E) The mRNA expression of p53 in hepatocytes. (F) The protein expression of p53 in hepatocytes. (G) Immunofluorescence staining for p53 in hepatocytes (original magnification, 40×). All the in vitro experiments were repeated at least three times independently. For the statistics of these panels, data are expressed as mean ± SD, ##P < 0.01 and ###P < 0.001 compared with DMSO, *P < 0.05 compared with DMSO plus ethanol, $P < 0.05 compared with ethanol plus curcumin. 139x142mm (600 x 600 DPI)
ACS Paragon Plus Environment
Page 32 of 34
Page 33 of 34
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 5. Curcumin inhibits ethanol-induced hepatocyte necroptosis through Nrf2/p53 pathway. (A) LO2 cells were treated with control siRNA or p53 siRNA for 24 h. Western blot analyses of p53 expression in hepatocytes. **P < 0.01 versus blank control. LO2 cells were treated with DMSO (0.02%, w/v) and/or ethanol and/or curcumin and/or Nrf2 siRNA and/or p53 siRNA at the indicated doses for 24 h. (B) MTT assay for evaluating the viability of LO2 cells. (C) HMGB1 levels in hepatocyte culture medium. (D) The mRNA expression of HMGB1, RIP1, and RIP3 in LO2 cells. (E) The protein expression of HMGB1, RIP1, RIP3, pMLKL, MLKL, p-JNK, and JNK in hepatocytes. (F-H) Immunofluorescence staining for RIP1, RIP3, and p-JNK in hepatocytes (original magnification, 40×). All the in vitro experiments were repeated at least three times independently. For the statistics of the panels above, data are expressed as mean ± SD, ##P < 0.01 and ### P < 0.001 compared with DMSO, **P < 0.01 and ***P < 0.001 compared with DMSO plus ethanol, $P < 0.05, $$P < 0.01, and $$$P < 0.001 compared with ethanol plus curcumin, &P < 0.05, &&P < 0.01, and &&&P < 0.001 compared with ethanol, curcumin plus Nrf2 siRNA. 183x195mm (600 x 600 DPI)
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Abstract graphic 28x20mm (600 x 600 DPI)
ACS Paragon Plus Environment
Page 34 of 34